David Kabakoff

Biography

David Kabakoff joined Sofinnova Ventures in 2007. He has more than 30 years of experience in R&D and executive management roles in venture backed biotech companies. David has been Chairman, President and/or CEO of five companies that have generated over $3B in aggregate exit value on $837M in invested capital. David currently serves as Chairman of Cebix, and is a board member of Intermune (ITMN), and Allylix. He also serves as Board observer at Histogenics and Nucana. He was formerly Chairman of Trius (TSRX), from inception through its sale in 2013 to Cubist for $707 Million, and Chairman of Amplimmune, from inception to its sale in 2013 to Astra-Zeneca for up to $500 Million. He was formerly an active advisor and board observer to IntelliKine. Prior to joining Sofinnova, David was CEO of Salmedix, which was sold to Cephalon for $200M. David has been active in the San Diego biotech industry since 1983 and has held senior roles at Hybritech, Corvas, Dura, and Spiros including three CEO roles leading to two IPOs and two trade sales. He has participated in raising over $1 Billion for venture backed companies and supervised over a dozen corporate partnerships. David holds a PhD in organic chemistry from Yale. He currently resides in Rancho Santa Fe with his wife, and he enjoys fine wine, travel, and skiing.

Research Interest

pharmacy